Sidley Austin represented Pyxis Oncology, Inc. on the deal. Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company, announced that it agreed to sell 8,849,371 shares of...
Pyxis Oncology’s $50 Million Shares Private Placement
Sagard Healthcare’s $200 Million Royalty Purchase Agreement with MannKind Corporation
Sidley Austin represented Sagard Healthcare in the transaction, and Cooley represented MannKind Corporation. Sagard Healthcare (Sagard) announced it entered into a royalty purchase agreement, under which...
Praxis Precision Medicines’ $264 Milion Collaboration and License Agreement with Tenacia Biotechnology
Sidley Austin represented Praxis Precision Medicines, Inc. in the transaction, and Ropes & Gray advised Tenacia. Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it has entered...
Novo Nordisk’s Partnership with Evotec SE to Launch Translational Drug Discovery Accelerator
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
Carlin Consumer Health’s Acquisition of Infirst USA Holdings
Sidley Austin LLP served as legal advisor to Carlin and Wilson Sonsini Goodrich Rosati acted as legal advisor to Infirst. Stifel acted as exclusive financial advisor...
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
Akeso’s US$5 Billion Licensing Agreement With Summit Therapeutics Title
Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
Yisheng Biopharma Co., Ltd.’s US$40 Million Royalty-Backed Financing From R-Bridge Healthcare Fund
Clifford Chance has advised Yisheng Biopharma Co., Ltd. on the deal, while Sidley Austin LLP and Maples and Calder advised R-Bridge Healthcare Fund. Yisheng Biopharma Co.,...
Tyra Biosciences’ $172.8 Million Initial Public Offering
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
Interius BioTherapeutics’ US$76 Million Series A financing.
Sidley Austin LLP advised Interius BioTherapeutics on the deal. Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene...
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
Tempest Therapeutics’ Merger With Millendo Therapeutics
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...